ARCHIVES

ASCO: Anastrozole Adds Treatment Option, But Tamoxifen Remains Standard

This article is from The Cancer Letter archive.

Vol. 28 No. 33 | September 13, 2002

Download PDF Visit The Full Archive

Related Articles

Funding opportunities listed.

November 12, 2004

Risk of Relapse Continues After Five Years of Therapy

August 29, 2008

NCI To Proceed With Guidelines Unless Board Strongly Disagree

May 9, 1980

NCI Board of Scientific Advisors also approved a new SBIR grant program for research on circulating cells in cancer detection.

March 26, 2004

NCI Begins TAILORx Study.

May 26, 2006

Moses, Earp to lead AACI. Funding opportunities.

September 12, 2003